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ineetakhanvilkar@Abstract A speciﬁc, precise and stability indicating high-performance thin-layer chromatographic
method for simultaneous estimation of pantoprazole sodium and itopride hydrochloride in
pharmaceutical formulations was developed and validated. The method employed TLC aluminium
plates precoated with silica gel 60F254 as the stationary phase. The solvent system consisted of
methanol:water:ammonium acetate; 4.0:1.0:0.5 (v/v/v). This system was found to give compact and
dense spots for both itopride hydrochloride (Rf value of 0.5570.02) and pantoprazole sodium
(Rf value of 0.8570.04). Densitometric analysis of both drugs was carried out in the reﬂectance–
absorbance mode at 289 nm. The linear regression analysis data for the calibration plots showed a
good linear relationship with R2¼0.998870.0012 in the concentration range of 100–400 ng for
pantoprazole sodium. Also, the linear regression analysis data for the calibration plots showed a
good linear relationship with R2¼0.999070.0008 in the concentration range of 200–1200 ng for
itopride hydrochloride. The method was validated for speciﬁcity, precision, robustness and
recovery. Statistical analysis proves that the method is repeatable and selective for the estimation
of both the said drugs. As the method could effectively separate the drug from its degradation
products, it can be employed as a stability indicating method.
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1. Introduction
Reﬂux of gastric contents into the oesophagus is a normal
phenomenon in most individuals, but it becomes pathological
when it causes troublesome symptoms or complications. Since the
introduction of proton pump inhibitors (PPIs), the treatment of
patients with gastroesophageal reﬂux disease (GERD) has dra-
matically improved [1]. GERD is very common and advances in
drug development over recent years have markedly improved
D.V. Bageshwar et al.276GERD management. A wide range of medications are currently
used in GERD treatment, including antacids, Gaviscon, sucral-
fate, histamine-2 receptor antagonists and prokinetics. However,
proton pump inhibitors (PPIs) remain the mainstay of treatment
for GERD owing to their profound and consistent inhibitory
effect on acid secretion. Despite the presence of a wide arma-
mentarium of therapeutic modalities for GERD, many areas of
unmet needs remain. Drug development has focused primarily on
improving PPI efﬁcacy, reducing the transient lower oesophageal
sphincter relaxation rate, attenuating oesophageal sensitivity and
developing oesophageal mucosal protectants [2].
Thus, many formulations are available for treatment of GERD.
Combination of pantoprazole sodium and itopride hydrochloride
is also available for treatment of GERD [2,3]. So, it is necessary to
have an analytical method so as to estimate both drugs simulta-
neously from its combined dosage form.
Literature survey reveals that spectrophotometric [4,5], HPLC
[6–9] and high performance thin layer chromatography (HPTLC)
[10,11] methods for the estimation of itopride hydrochloride from
bulk drugs and pharmaceutical formulation have been developed
whereas spectrophotometric [12], HPLC [13,14], RP-HPLC [15],
HPTLC [16] methods for the estimation of pantoprazole alone or
in combination with other drugs from pharmaceutical formulation
have been developed. However, no stability indicating method has
been reported so far for simultaneous estimation of both drugs in
combined pharmaceutical dosage form by HPTLC. This work
presents a stability indicating HPTLC method for the simulta-
neous estimation of both drugs in their combined pharmaceutical
dosage form, which can be used for its routine analysis in
laboratory.
The advantage of HPTLC is that large number of samples
can be simultaneously analysed in a shorter time period.
Unlike HPLC, this method utilises less quantities of solvents,
thus lowering the cost of analysis [17].
An ideal stability indicating chromatographic method
should estimate the drug and also be able to resolve the drug
from its degradation products. Hence an attempt has been
made to develop an accurate, rapid and reproducible method
for the determination of itopride hydrochloride and panto-
prazole sodium in presence of their degradation products for
their content analysis in pharmaceutical dosage forms contain-
ing this combination as per ICH [18] guidelines.2. Materials and methods
2.1. Chemicals and reagents
Itopride hydrochloride and pantoprazole sodium were pro-
cured as a gift sample. All other solvents and reagents were
purchased from S.D. Fine chemicals, Mumbai, India and were
of analytical grade.
2.2. Instrumentation
Spotting was done using Camag Linomat 5 sample applicator
(CAMAG, Switzerland) and Camag Hamilton Bonaduz
microlitre syringe (100 ml) on HPTLC aluminium plates pre-
coated with silica gel 60F254 (20 cm 10 cm with 250 mm
thickness; Merck, Germany). The plates were prewashed with
methanol for 30 min in a Camag twin trough glass chamber
closed with lid. The plates were activated at 110 1C for 30 min.The samples were spotted in the form of narrow bands having
length of 6 mm. The application position X and Y were kept
at 10 mm and 12 mm, respectively, to avoid edge effect. The
distance between the two bands was 10 mm. Spots were
applied at a constant rate of 15 nL/s using a nitrogen
aspirator. Linear ascending development of chromatogram
was carried out in a Camag twin trough glass chamber
saturated with the mobile phase for 15 min and chromatogram
run was kept up to 90 mm. Spectrodensitometric analysis of
the separated components was carried out using Camag TLC
Scanner 3 in the reﬂectance–absorbance mode at 289 nm using
a D2 lamp. The slit dimension used was 6.0 mm 0.3 mm
and sensitivity was kept at auto mode. Scanning speed
was 100 nm/s. Integration of the chromatogram was carried
out using Planar chromatography manager-winCATS
(CAMAG).2.3. Calibration plots
2.3.1. Calibration plot of pantoprazole sodium in methanol
A total of 10 mg of pantoprazole sodium was dissolved in
100 mL of methanol to obtain stock solution of 100 mg/mL.
Appropriate quantities of this stock solution were spotted to
obtain the concentration in the range of 100–400 ng.2.3.2. Calibration plot of itopride hydrochloride in methanol
A total of 10 mg of itopride hydrochloride was dissolved in
100 mL of methanol to obtain stock solution of 100 mg/mL.
Appropriate quantities of this stock solution were spotted to
obtain the concentration in the range of 200–1200 ng.2.4. Analysis of marketed formulation
To determine the content of itopride hydrochloride and
pantoprazole sodium in marketed capsules (label claim:
pantoprazole sodium 40 mg/capsule and itopride hydrochlor-
ide 150 mg/capsule), the contents of 20 capsules were weighed
and their average weight was determined. The content of
capsules containing sustained released pellets was ﬁnely
powdered.
Solution A: an amount equivalent to average weight of
capsule contents was transferred into a 100 mL volumetric
ﬂask containing 50 mL methanol. It was sonicated for 10 min
and contents were diluted to 100 mL with methanol. The
resulting solution was centrifuged at 3000 rpm for 5 min and
supernatant was collected.
Solution B: 1 mL of solution A was diluted to 10 mL of
methanol in a 10 mL volumetric ﬂask. 5 mL of solution B (200 ng
of pantoprazole sodium and 750 ng of itopride hydrochloride)
was applied on the TLC plate followed by development and
scanning. The analysis was repeated for six times.3. Method validation
3.1. Speciﬁcity
The speciﬁcity of the HPTLC method was ascertained by
analysing standard drug and sample solutions (marketed
formulation). The retention factor of pantoprazole sodium
Figure 1 Chromatogram of standard itopride hydrochloride (peak 1, Rf 0.5570.02) and pantoprazole sodium (peak 2, Rf 0.8570.03).
Table 2 Intra-day and inter-day precision results for pantoprazole sodium and itopride hydrochloride.
Drug Pantoprazole sodium Itopride hydrochloride
Concentration (ng) 100 200 300 375 750 1125
Intra-day precision
Mean drug content (%) 99.98 99.42 99.14 99.29 99.89 100.57
% R.S.D. 0.41 0.26 0.38 0.59 0.33 0.44
Inter-day precision
Mean drug content (%) 99.18 99.13 99.17 99.50 100.05 100.54
% R.S.D. 0.77 0.79 0.34 0.96 0.41 0.31
Table 1 Linear regression data for calibration plot of pantoprazole sodium and itopride hydrochloride (n¼3).
Parameters Pantoprazole sodium Itopride hydrochloride
Linearity range (ng) 100–400 200–1200
Correlation coefﬁcient (R2)7S.D. 0.998870.0012 0.999070.0008
Slope (mean7S.D) 15.279570.1542 5.541370.0513
Intercept (mean7S.D) 890.0311721.5457 589.7133730.2451
Table 3 Recovery data for pantoprazole sodium and
itopride hydrochloride.
Drug Level of %
recovery
Mean
recovery
R.S.D.
(%)
Pantoprazole
sodium
80 99.20 0.23
100 99.32 0.22
120 99.11 0.17
Itopride
hydrochloride
80 99.58 0.25
100 99.29 0.18
120 99.29 0.13
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ﬁrmed by comparing with that of the respective standards.
3.2. Precision
3.2.1. Repeatability
The system repeatability was determined by six replicates of
the prepared sample solutions. The repeatability of sample
application and measurement of peak area for the drugs were
calculated by repeating the assay six times at three different
concentration levels of 100, 200 and 300 ng for pantoprazole
sodium and 375, 750 and 1125 ng for itopride hydrochloride in
the same day for intra-day precision.
D.V. Bageshwar et al.2783.2.2. Intermediate precision
The intermediate precision was determined by six replicates of
the prepared sample solutions. The intermediate precision of
sample application and measurement of peak area was obtained
by the assay of six sample sets on different days at three different
concentration levels of 100, 200 and 300 ng for pantoprazole
sodium and 375, 750 and 1125 ng for itopride hydrochloride for
inter-day precision.Figure 2 Chromatogram of acid treated pantoprazole sodium. Peak
Pantoprazole sodium, Rf 0.82.
Table 4 Robustness results for pantoprazole sodium and itoprid
Parameters Pantoprazole sodium
Mean Rf % R.S
drug co
Mobile phase composition
3.8:0.8:0.5 (v/v/v) 0.83 0.28
3.9:0.9:0.5 (v/v/v) 0.83 0.49
4.1:1.1:0.5 (v/v/v) 0.86 0.53
4.2:1.2:0.5 (v/v/v) 0.86 0.88
Volume of mobile phase
25 mL 0.85 0.41
30 mL 0.87 0.31
Table 5 Results of analysis of marketed formulation.
Drug Label claim
(mg/capsule)
Amou
(mg)
Pantoprazole sodium 40 39.75
Itopride hydrochloride 150 150.14
aAverage of six determinations.3.3. Recovery studies
Recovery determination for pantoprazole sodium and itopride
hydrochloride was carried out at levels of 80%, 100% and
120%. The analysed samples were spiked with extra 80%,
100% and 120% of the standard drug and the mixture was re-
analysed by the proposed method. At each level of the
amount, three determinations were performed. This was done1: degradant, Rf 0.12, Peak 2: degradant, Rf 0.44 and Peak 3:
e hydrochloride.
Itopride hydrochloride
.D. of
ntent
Mean Rf % R.S.D. of
drug content
0.54 0.87
0.56 0.19
0.56 0.10
0.57 0.17
0.56 0.18
0.57 0.10
nt found Label claim
estimateda (%)
R.S.D. (%)
99.37 0.33
100.09 0.32
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formulations.3.4. Robustness
To evaluate the robustness of the developed method, deliberate
variations were made in the method parameters such as changing
the composition of the mobile phase and volume of mobile
phase. 200 ng of pantoprazole sodium and 750 ng of itopride
hydrochloride were applied on plates three times under different
conditions. The effects of the modiﬁed parameters on retention
factor and % drug content were calculated.
The following mobile phase compositions were tried (keep-
ing volume of ammonium acetate constant):F
F
digu
igu
egrMethanol:water:ammonium acetate; 3.8:0.8:0.5, v/v/v Methanol:water:ammonium acetate; 3.9:0.9:0.5, v/v/vre 3 Chromatogram of acid treated itopride hydrochloride. Peak
re 4 Chromatogram of alkali treated pantoprazole sodium. Pea
adant, Rf 0.69 and Peak 4: pantoprazole sodium, Rf 0.85.1:
k 1Methanol:water:ammonium acetate; 4.1:1.1:0.5, v/v/v Methanol:water:ammonium acetate; 4.2:1.2:0.5, v/v/v
The following changes were made in the volume of
mobile phase used for development of plates in twin trough
chamber: 25 mL of mobile phase
 30 mL of mobile phase4. Forced degradation studies
Pantoprazole sodium and itopride hydrochloride was sub-
jected to various stress conditions to affect their degradation.
Thus the acid induced, alkali induced, oxidative and dry heat
degradation was attempted. The degradation samples weredegradant, Rf 0.32, Peak 2: itopride hydrochloride, Rf 0.54.
: degradant, Rf 0.14, Peak 2: degradant, Rf 0.60, Peak 3:
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from its degradation products.
4.1. Preparation of acid and alkali induced degradation
product
Both the drugs were subjected to forced degradation sepa-
rately under acidic and alkaline conditions by reﬂuxing with
1 M HCl and 1 M NaOH, respectively, at 80 1C for a period of
6 h. The forced degradation in acidic and alkaline media was
performed in the dark in order to exclude the possible
degradative effect of light on the drug. A zero time sample
and stressed blank sample were also prepared.Figure 5 Chromatogram of alkali treated itopride hydrochloride. Peak
Peak 3: degradant, Rf 0.83.
Figure 6 Chromatogram of hydrogen peroxide treated pantoprazol
sodium, Rf 0.83.4.2. Preparation of hydrogen peroxide induced degradation
product
Forced degradation by hydrogen peroxide was performed by
reﬂuxing both drugs separately with hydrogen peroxide at
80 1C for a period of 4 h. A zero time sample and stressed
blank sample were also prepared.
4.3. Preparation of dry heat degradation product
The standard drug of pantoprazole sodium was placed in a hot
air oven at 110 1C for 2 h and itopride hydrochloride was
placed for 8 h at 110 1C to study dry heat degradation.1: degradant, Rf 0.37, Peak 2: itopride hydrochloride, Rf 0.54 and
e sodium. Peak 1: degradant, Rf 0.48 and Peak 2: pantoprazole
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5.1. Optimisation of chromatographic condition
The TLC procedure was optimised with a view to develop a
stability indicating assay method. Both the pure drug and the
degraded products were spotted on the TLC plates and run in
different solvent systems. But mobile phase consisting of metha-
nol:water:ammonium acetate (4.0:1.0:0.5, v/v/v) was able to give
characteristic spots for both drugs. By optimizing chromato-
graphic conditions such as having chamber saturation for 15
min, using 20 mL of mobile phase and activating plates before
spotting, we obtained a good resolution as well as a sharp and
symmetrical peak with Rf value of 0.5570.02 for itopride
hydrochloride and 0.8570.04 for pantoprazole sodium (Fig. 1).Figure 7 Chromatogram of hydrogen peroxide treated itopride h
degradant, Rf 0.79 and Peak 3: degradant, Rf 0.90.
Figure 8 Chromatogram of dry heat treated pantoprazole sodium.
degradant, Rf 0.68 and Peak 4: pantoprazole sodium, Rf 0.83.5.2. Validation of the developed method
5.2.1. Linearity
The calibration plot was found to be linear in the concentra-
tion range of 100–400 ng and 200–1200 ng for pantoprazole
sodium and itopride hydrochloride, respectively. The linearity
was validated by the high values of the correlation coefﬁcient.
The results are tabulated in Table 1.5.2.2. Precision studies
The repeatability (intra-day precision) and intermediate pre-
cision (inter-day precision) of sample application and mea-
surement of peak area were expressed in terms of % R.S.D
and was found to be less than 2% as depicted in Table 2.ydrochloride. Peak 1: itopride hydrochloride, Rf 0.57, Peak 2:
Peak 1: degradant, Rf 0.53, Peak 2: degradant, Rf 0.61, Peak 3:
Figure 9 Chromatogram of dry heat treated itopride hydrochloride. Peak 1: degradant, Rf 0.03, Peak 2: degradant, Rf 0.04 and Peak 3:
itopride hydrochloride, Rf 0.55.
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The recovery studies were carried out at 80%, 100% and
120% of the test concentration as per ICH guidelines. The
results of the recovery studies and its statistical validation are
given in Table 3.
5.2.4. Robustness
To evaluate the robustness of the method, selected parameter
was varied at different levels. The results presented in Table 4
indicate that Rf and % drug content were unaffected by small
variations in the selected method parameters.
Also the low values of % R.S.D. (o2) of % drug
content obtained after introducing small changes in mobile
phase composition and volume of mobile phase were
indicative of the robustness of the method as presented in
Table 4.
5.2.5. Speciﬁcity
The chromatogram of commercial formulation showed only
two peaks at Rf values of 0.85 and 0.55 for pantoprazole
sodium and itopride hydrochloride, respectively, indicating
that there is no interference of the excipients in the capsule
formulations.
5.2.6. Analysis of marketed formulation
The chromatograms of the drug extracted from commercial
formulation, exhibited two peaks at Rf value of 0.85 and 0.55
for pantoprazole sodium and itopride hydrochloride, respec-
tively. The mean drug content was found to be 39.75 mg and
150.14 mg for pantoprazole sodium and itopride hydrochlor-
ide with a % R.S.D of 0.33 and 0.32, respectively. The results
of the analysis of marketed formulation are given in Table 5.
5.3. Forced degradation results
Peaks obtained from samples degraded by treatment with
acid, alkali, hydrogen peroxide and dry heat treatment con-
tained well separated spots of the pure drugs and some
additional peaks at different Rf values. It is apparent fromFigs. 2–9 that the spots of the degradation products were well
resolved from those of the drugs. The peaks of itopride
hydrochloride and pantoprazole sodium were not signiﬁcantly
shifted in the presence of the degradation peaks, which
indicated the stability-indicating nature of the method.6. Conclusion
HPTLC determination of pantoprazole sodium and itopride
hydrochloride from pharmaceutical capsule dosage form
revealed no interference between two drugs and excipients of
the marketed capsule contents. The method is rapid, allowing
a high sample throughput necessary for routine analysis with
an added advantage of low solvent consumption. Also the
method is simple, rapid, speciﬁc and well suited for quantita-
tive estimation of both drugs individually from bulk drug and
from pharmaceutical preparations. As the method could
effectively separate the drugs from their degradation products
it can be employed as a stability indicating method.References
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